Chemotherapy Global Market Report 2026

Chemotherapy is a treatment approach that uses drugs or medications containing potent chemicals to destroy rapidly dividing cells in the body. These drugs may be administered individually or in combination for cancer treatment, as cancer cells multiply at an accelerated rate.

The primary product types used in chemotherapy include pumps, cannulas, catheters, and other related devices. Pumps refer to chemotherapy infusion pumps that are connected to patients and deliver controlled doses of medication gradually into the bloodstream. Chemotherapy services address cancers such as blood cancer, throat cancer, lung cancer, ovarian cancer, and stomach cancer, utilizing drug classes including alkylating agents, antimetabolites, antitumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, and others. These drugs are administered through oral and intravenous routes and are used across end users such as hospitals, research institutes, and other healthcare settings.

Tariffs have impacted the chemotherapy market by increasing the cost of imported chemotherapeutic drugs, infusion pumps, and medical devices. Asia-Pacific regions, particularly China and India, face the highest impact due to reliance on manufacturing hubs. Hospital and research institute segments are most affected, while domestic production expansion and local sourcing are providing some positive offsets by reducing dependency on imports.

The chemotherapy market research report is one of a series of new reports from The Business Research Company that provides chemotherapy market statistics, including chemotherapy industry global market size, regional shares, competitors with a chemotherapy market share, detailed chemotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy industry. This chemotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chemotherapy market size has grown rapidly in recent years. It will grow from $37.27 billion in 2025 to $41.95 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to rising prevalence of cancer, increasing government healthcare expenditure, advancement in chemotherapeutic drugs, growth of hospital infrastructure, adoption of intravenous chemotherapy.

The chemotherapy market size is expected to see rapid growth in the next few years. It will grow to $68.44 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to expansion of precision medicine, development of targeted therapies, increasing awareness about home-based chemotherapy, integration of digital health solutions, rising demand for combination therapies. Major trends in the forecast period include personalized chemotherapy regimens, oral chemotherapy adoption, combination drug therapy development, home-based chemotherapy delivery, advanced infusion device technologies.

The rising prevalence of cancer is expected to drive the growth of the chemotherapy market in the coming years. Cancer is a disease characterized by the uncontrolled growth of abnormal cells that can spread to other parts of the body. Chemotherapy uses powerful chemicals, either alone or in combination, to treat cancer by destroying rapidly dividing cancer cells. As the number of cancer cases increases, the demand for chemotherapy treatments is also expected to rise. For instance, in February 2024, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, more than 35 million new cancer cases are projected in 2025, representing a 77% increase compared with the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the chemotherapy market.

Major companies operating in the chemotherapy market are increasingly adopting strategic partnerships to support the commercialization of innovative medical devices that enhance chemotherapy services. These collaborations allow companies to combine complementary expertise, infrastructure, and market access to accelerate innovation in cancer care, improve patient outcomes, and address unmet clinical needs associated with chemotherapy treatment. For instance, in March 2023, EVERSANA, a US-based provider of global services to the life sciences industry, partnered with ChemoMouthpiece LLC, a US-based medical device company, to support the launch and commercialization of the Chemo Mouthpiece across the United States. The Chemo Mouthpiece is an intraoral cryotherapy device designed to deliver controlled cooling to the oral cavity during chemotherapy administration. By reducing blood flow to oral tissues, the device helps prevent and treat oral mucositis, one of the most common and painful side effects experienced by patients undergoing chemotherapy. This partnership highlights how strategic collaborations are advancing supportive care solutions within the chemotherapy market.

In February 2024, AbbVie, a US-based biopharmaceutical company, acquired ImmunoGen for $10.1 billion. This acquisition is anticipated to strengthen AbbVie's oncology portfolio by incorporating ImmunoGen's advanced antibody-drug conjugate technology. Through this strategic acquisition, AbbVie seeks to broaden its capabilities in developing next-generation therapies for patients facing multiple forms of cancer. ImmunoGen is a US-based company focused on the development of chemotherapy drugs.

Major companies operating in the chemotherapy market are GlaxoSmithKline plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Merck & Co Inc., Sanofi SA, Celgene Corporation, Bristol-Myers Squibb Company, Amgen Inc., Bayer AG, Almatic Pharma LLC, AstraZeneca Pharmaceuticals, Astellas Pharma Inc., Puma Biotechnology Inc., Clovis Oncology Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson Services Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Gilead Sciences Inc., Biogen Inc., Eisai Co. Ltd., Ipsen SA, Spectrum Pharmaceuticals Inc., Seattle Genetics Inc., Exelixis Inc., Karyopharm Therapeutics Inc., Incyte Corporation, Agios Pharmaceuticals Inc., Epizyme Inc., Blueprint Medicines Corporation, Array BioPharma Inc., BeiGene Ltd., Halozyme Therapeutics Inc., MacroGenics Inc., Immunomedics Inc., TG Therapeutics Inc., Verastem Inc.

North America was the largest region in the chemotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the chemotherapy market report during the forecast period. The regions covered in the chemotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chemotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemotherapy market includes revenues earned by entities by providing corticosteroids and hormonal agents as chemotherapy drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemotherapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses chemotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chemotherapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chemotherapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Pump; Cannula; Catheter; Other Product Types
• 2) By Service: Blood Cancer; Throat Cancer; Lung Cancer; Ovarian Cancer; Stomach Cancer
• 3) By Drugs: Alkylating Agents; Antimetabolites; Anti-Tumor Antibiotics; Topoisomerase Inhibitors; Mitotic Inhibitors; Other Drugs
• 4) By Route Of Administration: Oral; Intravenous
• 5) By End User: Hospitals; Research Institutes; Other End Users
• Subsegments:
• 1) By Pump: Infusion Pumps; Portable Pumps; Ambulatory Pumps
• 2) By Cannula: Peripheral Cannulas; Central Venous Catheters; Implantable Ports
• 3) By Catheter: Chemotherapy Catheters; PICC Lines
• 4) By Other Product Types: Safety Devices; IV Sets; Administration Sets
• Companies Mentioned: GlaxoSmithKline plc; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; Novartis AG; Pfizer Inc.; Merck & Co Inc.; Sanofi SA; Celgene Corporation; Bristol-Myers Squibb Company; Amgen Inc.; Bayer AG; Almatic Pharma LLC; AstraZeneca Pharmaceuticals; Astellas Pharma Inc.; Puma Biotechnology Inc.; Clovis Oncology Inc.; Takeda Pharmaceutical Company Limited; Johnson & Johnson Services Inc.; Mylan NV; Teva Pharmaceutical Industries Ltd.; AbbVie Inc.; Gilead Sciences Inc.; Biogen Inc.; Eisai Co. Ltd.; Ipsen SA; Spectrum Pharmaceuticals Inc.; Seattle Genetics Inc.; Exelixis Inc.; Karyopharm Therapeutics Inc.; Incyte Corporation; Agios Pharmaceuticals Inc.; Epizyme Inc.; Blueprint Medicines Corporation; Array BioPharma Inc.; BeiGene Ltd.; Halozyme Therapeutics Inc.; MacroGenics Inc.; Immunomedics Inc.; TG Therapeutics Inc.; Verastem Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.